Aktuellt
SENASTE
Following the acquisition of Combinostics and share issue, our new fair value range is SEK 4.6-5.4, on 2026E sales up 14% but EPS down 46%. We believe Combinostics complements SyntheticMR’s ambitions in the growing MRI diagnostics segment relating to novel Dementia treatments. We stress that uncertainties remain elevated, given the turbulence in management and disruptions to the company’s North American activities.
LÄS MER
